Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced that CEO Greg Divis will speak at several virtual investor conferences in September 2021. Key events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, Wells Fargo Virtual Healthcare Conference on September 10, H.C. Wainwright’s 23rd Annual Global Investment Conference on September 13, and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22. Live webcasts and recordings will be available for 90 days post-conference on the company's Investor Relations website.

DUBLIN, Ireland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming virtual investor conferences in September:

• 2021 Wells Fargo Virtual Healthcare Conference: Fireside chat on Friday, September 10, 2021 at 4:00 p.m. E.T.
• Morgan Stanley 19^th Annual Global Healthcare Conference: Fireside chat on Thursday, September 9, 2021 at 9:30 a.m. E.T.
• H.C. Wainwright’s 23^rd Annual Global Investment Conference: Fireside chat on Monday, September 13, 2021 at 7:00 a.m. E.T.
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: Fireside chat on Wednesday, September 22, 2021 at 10:45 a.m. E.T.

A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292

FAQ

What upcoming events is Avadel Pharmaceuticals participating in September 2021?

Avadel Pharmaceuticals will participate in several virtual investor conferences, including the Morgan Stanley Conference on September 9, Wells Fargo Conference on September 10, H.C. Wainwright Conference on September 13, and Oppenheimer Summit on September 22.

Who is the CEO of Avadel Pharmaceuticals?

Greg Divis is the Chief Executive Officer of Avadel Pharmaceuticals.

Where can I watch Avadel Pharmaceuticals' conference webcasts?

Webcasts of Avadel Pharmaceuticals' conferences will be available on their Investor Relations website for 90 days following each event.

What is FT218 developed by Avadel Pharmaceuticals?

FT218 is an investigational, once-nightly formulation of sodium oxybate aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy.

When is the Oppenheimer Fall Healthcare Summit?

The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is scheduled for September 22, 2021, at 10:45 a.m. E.T.